XPO1 and metastatic neoplasm: In both datasets, XPO1 mRNA level highly correlated with PIK3CA mRNA, supporting a potential XPO1 targeting in tumors with these clinically relevant genomic mutations found in 30−40% of ER+ metastatic tumors (Figure 1A).